Vyant Bio, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018
Cash Flows from Operating Activities:
Net loss
Loss from continuing operations
Net loss from discontinuing operations
Reconciliation of net loss to net cash used in operating activities, continuing operations:
Provision for bad debts
Amortization
Stock-based compensation
Amortization of operating lease right-of-use assets
Change in fair value of warrant liability, acquisition note payable and other derivatives
Amortization of discount of debt and debt issuance costs
Loss on disposal of fixed assets and sale of India subsidiary
Issuance of common stock to vendor
Interest added to Convertible Note
Modification of 2017 Debt warrants
Loss in equity-method investment
Change in fair value of siParadigm Earn-Out
Change in fair value of Excess Consideration note
Depreciation and amortization expense
Change in fair value of share-settlement obligation derivative
Change in fair value of financial instruments
Accretion of debt discount
PPL loan and EIDL grant forgiveness
Loss on conversion of debt
Loss on extinguishment of debt
Impairment of goodwill
Impairment of intangible assets
Other
Changes in operating assets and liabilities, net of impacts of business combination:
Accounts receivable
Other current assets
Other non-current assets
Accounts payable, accrued expenses and deferred revenue
Deferred rent payable and other
Due to Interpace Biosciences, Inc.
Trade accounts and other receivables
Inventory
Prepaid expense and other assets
Accounts payable
PPL loan and EIDL grant proceeds
Obligations under operating leases
Accrued expenses and other liabilities
Net cash used in operating activities, continuing operations
Net cash used in operating activities, discontinuing operations
Net cash used in operating activities

Cash Flows from Investing Activities:
Purchase of equipment
Patent costs
Purchase of cost method investment
Distributions from Joint Venture
Receipts from Excess Consideration Note
Proceeds from patent held for sale and equipment sales
Cash acquired from acquisition
Cash used in acquisition of vivoPharm, Pty Ltd., net of cash received
Net cash (used in) provided by investing activities, continuing operations
Net cash provided by (used in) investing activities, discontinuing operations
Net cash provided by investing activities

Cash Flows from Financing Activities:
Principal payments on obligations under finance leases
EIDL loan proceeds
Proceeds from borrowings on Silicon Valley Bank line of credit
Repayments of borrowings on Silicon Valley Bank line of credit
Principal payments on Convertible Note
Principal payments on Advance from NovellusDx, Ltd.
Fractional shares settlement paid in cash
Issuance of Series B Convertible Preferred Stock, net of issuance costs
Issuance of Series C Convertible Preferred Stock, net of issuance costs
Proceeds from sale of convertible note
Related party notes payable
Proceeds from Partners for Growth IV, L.P. term note
Payment of debt issuance costs
Principal payments on Silicon Valley Bank term note
Principal payments on long-term debt
Proceeds from lease financing
Principal payments on obligations under financing leases
Net cash (used in) provided by financing activities, continuing operations
Net cash used in financing activities, discontinuing operations
Net cash (used in) provided by financing activities

Effect of foreign currency exchange rates on cash and cash equivalents and restricted cash
Net (decrease) increase in cash and cash equivalents
Beginning
Ending
Cash and cash equivalents
Restricted cash
Cash and cash equivalents, beginning of year
Cash and cash equivalents, end of year
Supplemental disclosure of cash flow information:
Cash paid for interest
Common stock issued in VenturEast settlement
Fair value of common stock exchanged to settle Note Payable
Cash paid for income taxes
Non-cash investing activities:
Fair value of non-cash merger consideration
Issuance of common stock in exchange for warrants
Retirement of common stock - Oncospire
Lease remeasurement
Fixed assets acquired through finance lease arrangements
Derivative warrants issued with debt
Value of shares issued as partial consideration to purchase vivoPharm, Pty Ltd.
Conversion of debt and accrued interest into common stock
Increase in fair value of embedded conversion option
Exchanges of principal on Convertible Note for common stock
Partial pay-off of Convertible Note through note payable to Atlas Sciences, LLC
Fair value of warrants reclassified from liabilities to equity
2017 Debt
2017 Offerings
Total fair value of warrants reclassified from liabilities to equity
Beneficial conversion feature on Convertible Note
Accounts receivable, net
Other current assets
Fixed assets, net
Goodwill
Other noncurrent assets
Accounts payable, accrued expenses and deferred revenue
Deferred rent and other
Loss on sale of India subsidiary
Cash received in the sale of India subsidiary, net of cash transferred
Right-of-use assets obtained in exchange for new operating lease liabilities

Non-cash financing activities:
Conversion of Convertible Preferred Stock to Common Stock upon Merger
Conversion of 2020 Convertible Notes and accrued interest to Common Stock upon Merger
Exchange of Series B Convertible Preferred Stock for 2020 Convertible Notes
Related party note payable converted to 2020 Convertible Notes
Related party note payable exchanged for stock option exercise
Reclass warrant liability to equity upon Merger

Comments